Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757901 | 1.00 | PDE4A (0.34) | PDE4APDE4BPDE4CPDE4DCDK1 | |
| SCHEMBL23122434 | 0.86 | PDE4A (0.34) | PDE4APDE4BPDE4CPDE4DCDK1 | |
| SCHEMBL23122432 | 0.81 | CDK1 (0.39) | PDE4APDE4BPDE4CPDE4DCDK1 | |
| SCHEMBL23122489 | 0.81 | CACNA2D1 (0.33) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4409861 | 0.70 | PDE4A (0.33) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL23122695 | 0.69 | HPGD (0.38) | CDK1YTHDC1CDK2ALDH1A1 | |
| SCHEMBL23122693 | 0.67 | ALDH1A1 (0.32) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL25212510 | 0.66 | PDE4A (0.32) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23386572 | 0.66 | ADORA2A (0.37) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL1397023 | 0.66 | CDK1 (0.37) | CDK1YTHDC1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4031552-B1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4031552-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2022-07-27 | — | — | EP | disclosed |
| CN-114728975-A | Azole-fused pyridazin-3 (2H) -one derivatives | 武田药品工业株式会社 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021055326-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | GPR139, GPR119, GPR39 | PDE4A 822/4885PDE4B 665/4885PDE4C 810/4885 |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | GPR139, GPR119, GPR39 | PDE4A 822/4885PDE4B 665/4885PDE4C 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.